**Breaking new : Oncodesign offers assessment solutions to evaluate innovative preventive and therapeutic strategies for COVID-19 (sars-CoV-2). Click 'Request More Info' button on this page to ask about offer details.**
SOLUTION PROVIDER ACROSS MAJOR THERAPEUTIC AREAS
Oncodesign is a leading biopharmaceutical company that meets the needs of innovation in the health industry through precision medicine. The company has built an industrial model of innovation to orientate new therapeutic molecules to fight serious illnesses with unmet medical needs : cancer, immuno-oncology, immunology, inflammation and infectious diseases.
Starting out from your targets or your molecules, we orient, drive and perform discovery or development programs to select the best drug candidates thanks to our following services:
From target validation to preclinical candidate and IND
Strategic discovery program management up to clinical phase
‐ Proof of concept – Pharmacology
‐ Pharmaco imaging
‐ Targeted radiotherapy
‐ Biopharmaceutical products services
WHAT CAN YOU EXPECT FROM ONCODESIGN?
Oncodesign recognizes it is a significant investment for clients to select and access specialized technologies and expert scientist resources with an extensive knowledge of pharmaceutical drug discovery and development. When it comes to outsourcing client projects, quality, innovation, time and agility are key components for clients seeking to build a trusted and long-term relationship.
Helping our clients identify new approaches and anticipate tomorrow’s challenge
Oncodesign is a vector for therapeutic innovation. As such, for over two decades, Oncodesign has invested in a continuum of technologies platforms (Predict®, Xmice®, T.O.T.®, OncoSNIPE® and Pharmimage®) to support Precision Medicine innovation model. These platforms come from the technological specificities of the company, thanks to a mesh pattern of scientific skills, knowledge & know-how and innovative technologies.
Thanks to these platforms we support our clients investigating and establishing preclinical proof-of concept of a multitude of therapeutic approaches and products.
So far, 5,000 advanced preclinical or clinical therapeutic solutions have been assess ranging from new chemical entities, biologics, cell or gene therapy, systemic targeted radiotherapies as well as combination therapies.
A strong track record
Oncodesign’s multidisciplinary research teams and our seasoned management staff have had true accomplishments in drug discovery, having delivered more than 20 pre-clinical candidates to clients, partners and internally. A significant number of pre-clinical candidates, including first-in-class, have already progressed into clinical trials
Besides, we have been serving more than 800 clients amongst pharmaceutical, biotech and life-science companies around the world to assess numerous treatment options in preclinical proof-of-concept studies across major therapeutic areas.
We also take pride in the trust and fidelity of our clients proven by long term agreements and sustained repeat business.
Mutual understanding & customized project management
We first listen to and understand clients’ requirements to design their tailored studies or discovery programs. Together, we set key milestones to reach endpoints such as activity, selectivity, pharmacological or ADME profile and toxicity, within a defined frame time.
To allow our client to take informed and on-time decisions, we implement program or project management to insure constructive and regular discussions.
A collaborative mindset from a team with mix of backgrounds, experiences & skills
For Oncodesign "we must succeed together". The creation of value arising from reciprocity, that is to say balanced, and transparent exchanges at all levels, with our partners, our clients.
We acknowledge the diversity of our clients’ cultures and needs. However, all clients seek our team ability to design and perform studies or discovery programs encompass highest pharmaceutical standard to deliver robust data and products. Oncodesign combines a biotechnology mindset to seek for all fast track pathways along with a sense of service to deliver and communicate on purpose.
Our management, scientific and business development teams encompass a mix of origin, experiences and skills. This diversity is a valuable asset to Oncodesign, allowing us to understand each unique client and to drive discovery programs knowing that no two projects will ever be the same.
Quality meeting client satisfaction & regulatory requirements
Oncodesign’s quality management aims to set-up a framework to monitor our ability to meet client satisfaction in drug discovery and development along with regulatory requirements.
We drive our quality management process in a continuous improvement approach, as part of the comprehensive company management. As such, Oncodesign welcomes inspections and audits from clients & health authorities for the work being considered.
Furthermore, for non-clinical development, Oncodesign is GLP compliant with grade A certification from French authorities (ANSM).
DRIVE™ (DRug Integrative discoVEry): an integrated drug discovery and development solution from hit finding to IND filing.
The drug discovery process is faced with a growing pressure to deliver novel therapeutic agents faster and with a potential for a lower attrition in the clinic, to treat diseases with high unmet medical needs. For the past 25 years, Oncodesign has been building an integrated drug discovery engine for precision medicine enabling to orient, drive the discovery and deliver pre-clinical candidates successfully.
DRIVE™ is part of our continuous improvement in the integrated drug discovery support. It gives access to a comprehensive continuum of technological platforms together with our strategic partners’ complementary expertise. DRIVE™ is a smart and agile solution to help clients streamline their drug discovery and development programs and to make best use of their resources and achieve optimum results.
DRIVE™ offers a complete drug discovery and development solution through the whole value chain from hit finding to IND filing, aiming to accelerate the entry of the client new chemical entities into clinic within a 3 to 4 years timeframe to deliver an IND.
Our distinctiveness comes from our expertise in the breadth and depth of innovative service
DRIVE™ encompasses all drug discovery skills, expertise and platforms to deliver drug in major therapeutic areas, such as oncology, immuno-oncology, immuno-inflammation and inflammation.
The quality of the starting hits impact the future likelihood of success to Pre-clinical candidate. Additionally, clients seek for rapid optimization and development cycles from hit finding, hit to lead and drug candidates.
DRIVE™ enables our clients with the best possible options to identify and validate promising hit series, owing to the innovative technologies provided by our strategic partners, HitGen, 2Bind and others.
DRIVE™ also, sustains the Hit to Pre-Clinical Candidate process in a Multiparametric optimization mode and with a fast streamlined testing of every newly synthesized compounds. This holds from our experienced multi-disciplinary teams in the drug discovery process, efficiently interacting to allow rapid iteration and results sharing between medicinal chemistry, in vitro and in vivo pharmacology and DMPK.
mission’s is to “discover innovative new therapies effective against serious
illnesses with unmet medical needs”. Within the frame of IDMIT (Infectious
Disease Models and Innovative Therapies), a national French research
infrastructure, Oncodesign offers solutions to evaluate innovative preventive
and therapeutic strategies in particular for HIV/AIDS, Coronavirus, Dengue,
Chikungunya, influenza, yellow fever, etc.
Oncodesign offers straightforward, immediately available or shortly validated in vitro & in vivo models, including imaging studies in infected Non Human Primate to assess Covid-19 infection and its associated complications, such as inflammatory or immune reactions (fibrosis, cytokine storms).
In vitro models
Spike S - ACE (protein-protein interactions)
Sars-Cov-2 infected cells: Human (lung, intestine, broncho-pulmonar), Monkey (kidney)
SARS-CoV-2 infected animal models
Non-Human Primate Monkey
of a COVID-19-like disease
Early inflammatory response
Golden Syrian Hamster
& lung inflammation with diffuse alveolar damage
Additional models associated to Covid-19 complications
COVID-19 patients may progress to Acute Respiratory Distress Syndrome (ARDS), of which a subset of survivors will develops lung fibrosis. Within, this frame, Oncodesign has a validated Bleomycin induced pulmonary fibrosis model in C57BL/6 mice.
Additionally, early research indicate that many of the fatal cases of COVID-19 result from over-activation of a person’s immune system, referred to as a “cytokine storm”, could be key in preventing the virus deadly effects.
To investigate number of strategies, both repurposing and new ones, Oncodesign can assess the reduction of activation of immune cells by assessing cytokine production or specific signaling pathways dependent on pro-inflammatory cytokines.
We are also focusing our efforts to provide potentially more predictive models. Oncodesign's Chi-Mice® technological platform consists of:
Reconstituted human immune system models
Patient-derived xenografts (PDX) in immunodeficient mice and rats
PDX combined with human immune system models
Specific model development via our international biological resource collection network
"Hi there, I will use their services again, as it works really well with the progress updates and the services in general. I am in favor of the principles of the system. However, as a local site we have local processes for the generation of for instance our PO numbers and local payment details and it is important for us to have these details included when finalizing orders to avoid additional complications, and to obey to the local compliance requirements. Thanks, Mia"
Oncodesign has not received any endorsements.